Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell.

Chronic Graft-Versus-Host Disease Clinical Trial

— CSM/EICH2010  

Official title:

Phase 1/2 Study of Treatment of Refractory Acute Graft-Versus-Host Disease After First Line Therapy by Sequential Infusion of Expanded In-Vitro Allogenic Mesenchymal Stem Cell

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01956903
• Other study ID #: CSM/EICH2010
• Secondary ID: 2010-020947-11
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: September 30, 2013
• Last updated: September 30, 2013
• Start date: January 2010
• Est. completion date: September 2013

Study information

• Verified date: September 2013
• Source: Grupo Espanol de trasplantes hematopoyeticos y terapia celular
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Agencia Española de Medicamentos y Productos Sanitarios
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and efficacy of sequential infusion of allogenic mesenchymal stem cells (MSC) expanded "in vitro" in treating patients with acute graft-versus-host disease refractory to first-line therapy.

Description:

1. Ethical considerations:

• The study will be conducted in accordance with the requirements expressed in the Declaration of Helsinki (Hong Kong revision, September 1989) and following the recommendations of the Good Clinical Practice of the Clinical Trials (document 111/3976/88, July 1990 ) and Spanish legislation (Royal Decree 561/1993, published in April 16th Official State Bulletin "BOE"; May 13th, 1993) laying down the requirements for conducting clinical drug trials.

• Every subject will receive a written document called "Patient Information Sheet" that contains information about the following aspects of clinical trial: a) Aim of the study, methodology, study treatment and alternative therapies, expected benefits for himself or society, risks of the study and possible adverse events, number of visits and additional tests.

b) Voluntary nature of their participation and ability to withdraw at any time, without thereby altering the doctor-patient relationship.

c) People who have access to the data of the volunteer and how they maintain the confidentiality of the data.

d) How to contact with the investigator if necessary.

• The investigator will obtain the informed consent of the subject or, failing that, from a legal representative. The subject is preferably expressed written consent or, alternatively, orally to the research team independent witnesses who declare in writing under its responsibility.

• The person participating in the clinical trial or his representative may revoke the consent at any time.

2. Data Access:

• In order to ensure the confidentiality of the trial data, only have access to them, the researcher and his team, the test monitor and the Clinical Research Ethics Committee of the corresponding center or purposes under test and relevant health authorities.

• Protection of data: The content of the data collection forms and the documents generated during the study, will be protected from unauthorized uses by people outside the research and, therefore, will be considered strictly confidential and will not be disclosed to third parties except to those specified in the preceding paragraph.

3. Data Collection:

• Data colection forms will be dated and signed by the authorized principal investigator.

• Unknown data will be collected as "NA"(not available).

• Unusual or extreme results, or that do not match the expected sequence will be checked and corrected by initialing, signing and providing an explanation.

• Laboratory results that exceed normal limits established by the laboratory of the center, should be checked by the researcher and their significance will be noted next to the data, by initialing and signing.

4. Statistical Analysis:

• Baseline data will be analyzed using descriptive statistics and demographics (mean, median, standard deviation, minimum, maximum, and number of valid cases) for quantitative variables and absolute and relative frequencies for categorical variables.

• The primary efficacy objective is to determine the response rate of graft versus host disease (confidence intervals 95%).

• The primary safety objective is to determine the incidence of adverse events and toxicity related to the administration of the CSM (confidence intervals 95%).

• Secondary objectives: analyze overall survival and disease-free survival by the Kaplan-Meier method.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: September 2013
• Est. primary completion date: September 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patients with hematologic malignancies who have undergone allogenic stem cell transplantation and who are diagnosed with acute graft-versus-host-disease refractory to first-line treatment.

• Patients must have adequate cardiac function without evidence of uncontrolled hypertension, congestive heart failure or myocardial infarction within 6 months prior to the process.

• Adequate pulmonary function with no evidence of severe obstructive or restrictive pulmonary disease.

• Be able to understand the information and sign the informed consent.

Exclusion Criteria:

• Patients with uncontrolled disease or in progress at the time of treatment.

• Patients with uncontrolled bacterial, viral or fungal infection.

• Patients with inadequate cardiac or pulmonary function.

• Patients who do not have the required donor.

• Women pregnant or at risk of pregnancy by inadequate contraceptive measures.

• Patients who in the opinion of the investigator are not able to participate in the study.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Graft-Versus-Host Disease
• Graft vs Host Disease

Intervention

Genetic:
• Allogenic Mesenchymal Stem Cell
Expanded in-Vitro Allogenic Mesenchymal Stem Cell (authorized by Spain, "Agencia Española de Medicamentos y Productos Sanitarios" with number 06-076)

Locations

Country	Name	City	State
Spain	Grupo Espanol de trasplantes hematopoyeticos y terapia celular	Madrid

Sponsors (1)

Lead Sponsor	Collaborator
Grupo Espanol de trasplantes hematopoyeticos y terapia celular

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse effects	Infusion related.; Infection Rate.	from infusion to 100 days after stem cell transplant	Yes
Secondary	efficacy	Acute Graft-Versus-Host Disease response rate.	Acute Graft-Versus-Host Disease period (100 days)	No